Liquidia Co. (NASDAQ:LQDA) Stock Holdings Increased by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in Liquidia Co. (NASDAQ:LQDA) by 17.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,540 shares of the company’s stock after buying an additional 2,298 shares during the quarter. SG Americas Securities LLC’s holdings in Liquidia were worth $187,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LQDA. Fortitude Family Office LLC bought a new position in shares of Liquidia during the fourth quarter valued at approximately $26,000. UBS Group AG grew its holdings in shares of Liquidia by 134.0% during the second quarter. UBS Group AG now owns 7,948 shares of the company’s stock valued at $35,000 after purchasing an additional 4,552 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Liquidia during the second quarter valued at approximately $38,000. BNP Paribas Arbitrage SA grew its holdings in shares of Liquidia by 42.8% during the second quarter. BNP Paribas Arbitrage SA now owns 10,682 shares of the company’s stock valued at $47,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Liquidia by 101.3% during the second quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock valued at $55,000 after purchasing an additional 3,524 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia Price Performance

LQDA opened at $13.95 on Friday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.62 and a beta of 0.16. Liquidia Co. has a 1-year low of $5.71 and a 1-year high of $16.99. The business has a 50 day moving average price of $14.77 and a two-hundred day moving average price of $10.80.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). The firm had revenue of $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. Equities analysts expect that Liquidia Co. will post -1.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on LQDA shares. LADENBURG THALM/SH SH upped their target price on Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, December 21st. Wedbush reissued an “underperform” rating and issued a $3.00 price objective on shares of Liquidia in a report on Thursday, December 21st. HC Wainwright increased their price objective on Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, March 14th. Bank of America increased their price objective on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a report on Wednesday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Insider Activity

In other news, insider Jason Adair sold 4,657 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.81, for a total transaction of $73,627.17. Following the completion of the sale, the insider now owns 108,640 shares in the company, valued at approximately $1,717,598.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Jason Adair sold 4,657 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.81, for a total transaction of $73,627.17. Following the completion of the sale, the insider now owns 108,640 shares in the company, valued at approximately $1,717,598.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger Jeffs sold 28,583 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total value of $452,183.06. Following the sale, the chief executive officer now owns 835,345 shares of the company’s stock, valued at approximately $13,215,157.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,605 shares of company stock worth $862,904. Insiders own 31.60% of the company’s stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).